Novo Nordisk (NVO) said Friday its phase 3b trial comparing subcutaneous semaglutide 7.2 mg with semaglutide 2.4 mg and placebo achieved its primary endpoint by demonstrating a "statistically significant and superior" weight loss at week 72.
The trial, which involved 1,407 adults with obesity, showed participants administered with semaglutide 7.2 mg on a weekly basis alongside lifestyle interventions achieved a 20.7% weight loss from a mean baseline weight of 113 kg. This compares to a 17.5% reduction with semaglutide 2.4 mg and 2.4% with placebo.
The trial demonstrated that 33.2% of participants receiving semaglutide 7.2 mg achieved at least 25% weight loss, outperforming the 16.7% with semaglutide 2.4 mg and 0% with placebo.
Novo Nordisk said the semaglutide 7.2 mg demonstrated a safe and well-tolerated profile, with most adverse events being mild to moderate gastrointestinal issues that diminished over time.
Novo Nordisk shares were 2.5% lower in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.